Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05911100 |
Other study ID # |
691-?? |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 25, 2020 |
Est. completion date |
December 31, 2024 |
Study information
Verified date |
June 2023 |
Source |
Meshalkin Research Institute of Pathology of Circulation |
Contact |
Oksana Kamenskaya, PhD, MD |
Phone |
+79139458972 |
Email |
o_kamenskaya[@]meshalkin.ru |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
This clinical study will create an evidence base for rehabilitation approach, which will be
used for restoration of pulmonary ventilation and gas exchange, increase of tolerance to
physical load reduced in patients who underwent COVID-19.
The aim of the present clinical study is to evaluate the effectiveness of medical
rehabilitation of COVID-19 patients based on the study of individual physiological parameters
of oxygen metabolism and reserve capabilities of the cardiovascular and respiratory systems.
Description:
After an interview about the possibility of taking part in the study, the patient is
presented with an informed consent form, explaining all the questions of interest. In the
case of consent to participate in the study, the patient and the researcher fill out all the
necessary fields of the two copies of the informed consent and sign it. If necessary, the
researcher re-explains any information about the study. One copy of the informed consent
remains with the patient, and the second copy is kept by the investigator, as required by
Good Clinical Practice.
Once informed consent is obtained, an Individual Registration Card (IRC) is completed for the
patient enrolled in the study. Completion of the IRC also continues until completion of the
second phase of rehabilitation.
Pulmonary functional tests, cardiopulmonary stress testing (CPT) are performed on day 1 or 2
of inclusion of the patient in the rehabilitation program of "Federal Research Center for
Fundamental and Translational Medicine" (FRC FTM) using MasterScreen Pneumo (Jaeger, Germany)
and Oxycon Pro ergospirometry systems (Jaeger, Germany), in accordance with international
standards. The indexes of external respiration are brought to BTPS conditions, and gas
exchange - STPD. The protocol of stress testing is chosen individually, based on the proper
values in accordance with the age, sex and anthropometric data of the patient. The study is
conducted up to the individual maximum, followed by a recovery period. The anaerobic
threshold is determined using the V-slope method. After peak load is reached, it is gradually
reduced. Observation is continued until complete recovery of hemodynamic parameters, gas
exchange, in case of adverse symptoms - until their disappearance. Repeated testing is
performed after the rehabilitation program, before discharge from the FTC MTF.
Thoracic MSCT is performed on day 1-2 of inclusion of a patient into the rehabilitation
program of the FRC FTM to assess the lesion of the bronchopulmonary system after COVID-19.
Questionnaires describing the severity of the underlying disease (mMRC respiratory impairment
scale, BODE pulmonology risk scale, SMRT-CO respiratory support need scale), and SF-36
quality of life questionnaire are completed at study inclusion and after the rehabilitation
program, before discharge from the FRC FTM.